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Abstract To investigate the trends of antimicrobial
resistance in pathogens isolated from surgical site infec-
tions (SSI), a Japanese surveillance committee conducted
the ﬁrst nationwide survey. Seven main organisms were
collected from SSI at 27 medical centers in 2010 and were
shipped to a central laboratory for antimicrobial suscepti-
bility testing. A total of 702 isolates from 586 patients with
SSI were included. Staphylococcus aureus (20.4 %) and
Enterococcus faecalis (19.5 %) were the most common
isolates, followed by Pseudomonas aeruginosa (15.4 %)
and Bacteroides fragilis group (15.4 %). Methicillin-
resistant S. aureus among S. aureus was 72.0 %. Vanco-
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mycin MIC 2 lg/ml strains accounted for 9.7 %. In
Escherichia coli, 11 of 95 strains produced extended-
spectrum b-lactamase (Klebsiella pneumoniae, 0/53
strains). Of E. coli strains, 8.4 % were resistant to ceftaz-
idime (CAZ) and 26.3 % to ciproﬂoxacin (CPFX). No
P. aeruginosa strains produced metallo-b-lactamase. In
P. aeruginosa, the resistance rates were 7.4 % to tazo-
bactam/piperacillin (TAZ/PIPC), 10.2 % to imipenem
(IPM), 2.8 % to meropenem, cefepime, and CPFX, and
0 % to gentamicin. In the B. fragilis group, the rates were
28.6 % to clindamycin, 5.7 % to cefmetazole, 2.9 % to
TAZ/PIPC and IPM, and 0 % to metronidazole (Bacte-
roides thetaiotaomicron; 59.1, 36.4, 0, 0, 0 %). MIC90 of
P. aeruginosa isolated 15 days or later after surgery rose in
TAZ/PIPC, CAZ, IPM, and CPFX. In patients with
American Society of Anesthesiologists (ASA) score C3,
the resistance rates of P. aeruginosa to TAZ/PIPC and
CAZ were higher than in patients with ASA B2. The data
obtained in this study revealed the trend of the spread of
resistance among common species that cause SSI. Timing
of isolation from surgery and the patient’s physical status
affected the selection of resistant organisms.
Keywords Surgical site infections  Surveillance 
Antibiotic susceptibility  Bacteroides fragilis group
Introduction
Surgical site infections (SSIs) are one of the most impor-
tant causes of hospital-acquired infections. In a prevalence
survey undertaken in 2010 by the Japanese Healthcare-
Associated Infections Surveillance [1] (JHAIS), 7.6 % of
patients who had undergone surgical procedures developed
SSIs. The occurrence of an SSI results in reduced quality of
life, increased length of hospital stay, increased likelihood
of mortality, and markedly increased costs [2–5]. Appro-
priate antimicrobial therapy is mandatory not only to
improve the prognosis of patients with SSIs but also to
minimize the occurrence of antibiotic-resistant organisms.
To use antibiotics appropriately, information on the anti-
biotic susceptibility of the organisms isolated from SSIs is
of particular value. The purpose of this study was to
investigate the antibiotic susceptibility of the organisms
isolated from SSIs by a nationwide survey, and to reserve
the data to compare with the subsequent incidence of the
isolation of antibiotic-resistant organisms with periodic
surveillance.
Methods
The Japanese surveillance committee, consisting of the
Japanese Society of Chemotherapy, Japanese Association
for Infectious Disease, and Japanese Society for Clinical
Microbiology, conducted the ﬁrst nationwide surveillance
of antimicrobial susceptibility in organisms isolated from
SSI. The study protocol was prepared by the working group
and accepted by the governing board of the Japanese sur-
veillance committee. Ethics approval was the responsibility
of each study center. All patient data were reported anon-
ymously to the study database. If necessary, investigators
asked for formal approval of the protocol by the regional
ethics committee.
The diagnosis of SSI was made based on deﬁnitions
stated in the guidelines issued by the National Nosocomial
Infections Surveillance [6] (NNIS) system. The criterion
for the diagnosis of SSI was an infection that occurred
within 30 days after the operation. SSI was deﬁned by any
of the following clinical criteria: documentation by an
attending trauma surgeon indicating the presence of an SSI,
the administration of antibiotics speciﬁcally for a surgical
site, and the opening or packing of a surgical wound based
on its appearance. Site infections were further classiﬁed by
CDC criteria into superﬁcial incisional, deep incisional, or
organ/space SSI. Superﬁcial incisional SSI involved only
the skin or subcutaneous tissues, whereas deep incisional
SSI involved the deep soft tissues of the incision. Organ/
space infections involved any location beyond the incision
that was manipulated during surgery.
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Seven principal organisms (Escherichia coli, Klebsiella
pneumoniae, Enterobacter cloacae, Pseudomonas aeru-
ginosa, Bacteroides fragilis group, Staphylococcus aureus,
Enterococcus faecalis) isolated from SSI were collected in
27 medical centers in Japan between April 2010 and
December 2010, and were referred to a central laboratory
(Research Center for Anti-infective Drugs of Kitasato
Institute) for testing. Shipped strains were kept at -80 C
until antimicrobial susceptibility testing was conducted.
Re-identiﬁcation and cultivation of the strains yielded
evaluable strains. All isolates were susceptibility tested by
the broth microdilution method as described by the Clinical
and Laboratory Standards Institute [7, 8] (CLSI). In dap-
tomycin, a frozen plate prepared by Eiken Chemicals was
used. As culture medium, cation-adjusted Mueller–Hinton
broth (CAMHB) was used (concentration of calcium was
adjusted to 50 mg/l).
The accuracy of determination of theminimum inhibitory
concentrations (MICs) of antibacterial agents was con-
trolled according to the recommendations of the CLSI. To
detect b-lactamase production in gram-negative bacteria, a
Nitroceﬁn disk (Ceﬁnase; BD, Japan) was used according to
the reference manual supplied by the manufacturer. The
Cica-Beta Test (Kanto Chemical, Tokyo, Japan), a recently
developed rapid method, was used to detect extended-
spectrum b-lactamase (ESBL) and metallo-b-lactamase
(MBL)-producing gram-negative bacteria by directly
scraping the colony and applying it on the disk [9, 10].
Thirty-one different antibacterial agents were employed:
especially, vancomycin, teicoplanin, linezolid, clindamycin,
minocycline, erythromycin, sulfamethoxazole-trimetho-
prim, arbekacin, and rifampin for methicillin-resistant
Staphylococcus aureus (MRSA), ceftazidime cefepime,
piperacillin/tazobactam, imipenem, meropenem, doripe-
nem, biapenem, panipenem, aztreonam, ciproﬂoxacin, lev-
oﬂoxacin, pazuﬂoxacin, and gentamycin for P. aeruginosa,
and metronidazole, clindamycin, cefmetazole, ﬂomoxef,
ampicillin/sulbactam, piperacillin/tazobactam, and ﬁve
kinds of carbapenems for B. fragilis group). Because dap-
tomycin was not commercially available at the start of this
study, daptomycin was excluded from the initial protocol.
Separately, the MIC of daptomycin against MRSA was
determined afterward by the central laboratory using the
same MRSA isolates.
Survey items concerning each patient’s characteristics
were as follows: type of surgery, type of SSI (incisional,
organ/space), American Society of Anesthesiologists
(ASA) physical status classiﬁcation score, duration of
therapeutic antibiotic use, and postoperative hospital stay
until organism isolation. Statistical analysis was performed
as follows: categorical variables were compared by the v2
test with Yates’ correction or Fisher’s exact test when
necessary, using Microsoft Excel 2003.
Results
A total of 702 isolates (incisional 328, organ/space 374
strains) were included in the investigation. S. aureus
(20.4 %) and E. faecalis (19.5 %) were the most common
isolates. P. aeruginosa (15.4 %) and B. fragilis group
(15.4 %) were next, with E. coli, Enterobacter cloacae,
and K. pneumoniae accounting for 13.5, 8.8, and 7.7 % of
isolates, respectively. Five organisms were isolated from
pediatric patients. Incidences of S. aureus and P. aeru-
ginosa isolated from incisional SSI were signiﬁcantly
higher than those of organ/space SSI. In contrast, the
incidence of Enterobacteriaceae isolated from organ/space
SSI was signiﬁcantly higher than from incisional SSI
(Table 1).
Three hundred thirty-six strains were isolated from
lower gastroenterological surgery, 190 strains from hepa-
tobiliary and pancreatic surgery, 73 strains from upper
gastroenterological surgery, 68 strains from general sur-
gery including breast surgery, and 30 strains from thoracic
surgery (cardiovascular and respiratory tract). As for the
duration of antimicrobial prophylaxis, only 18.5 % of
patients had their antimicrobial prophylaxis discontinued
within 24 h. At 48 h after the end of surgery, 56.2 % of
patients were still receiving prophylaxis, and 11.7 % con-
tinued to receive prophylaxis for more than 5 days. Lead-
ing isolates were S. aureus in upper gastroenterological
surgery, general surgery, and thoracic surgery, E. faecalis
in hepatobiliary and pancreatic surgery, and B. fragilis
group in lower gastroenterological surgery.
Antibiotic susceptibility of gram-positive organisms,
including methicillin-sensitive S. aureus (MSSA), MRSA,
and E. faecalis, gram-negative organisms, including
E. coli, K. pneumoniae, E. cloacae, and P. aeruginosa, and
B. fragilis group is shown in Table 2. MRSA was 72.0 %
among S. aureus. Vancomycin MIC 2 lg/ml strains
accounted for 9.7 % (Table 5). In E. coli, 11 of 95 strains
Table 1 Isolated organisms according to types of surgical site
infection (SSI)
Organisms Incisional
SSI
Organ/space
SSI
P value
Staphylococcus aureus 81 (24.7) 62 (16.6) 0.008
MRSA 53 (16.2) 50 (13.4)
MSSA 28 (8.5) 12 (3.2)
Enterococcus faecalis 55 (16.8) 82 (21.9) 0.085
Enterobacteriaceae 84 (25.6) 122 (32.6) 0.042
Escherichia coli 37 (11.3) 58 (15.5)
Klebsiella pneumoniae 17 (5.2) 36 (9.6)
Enterobacter cloacae 30 (9.1) 28 (7.5)
Pseudomonas aeruginosa 63 (19.2) 45 (12.0) 0.009
Bacteroides fragilis group 45 (13.7) 63 (16.8) 0.252
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(11.9 %) produced extended-spectrum b-lactamase (ESBL),
and none of the strains produced ESBL in K. pneumoniae.
Of E. coli strains, 8.4 % were resistant to ceftazidime
(CAZ), 20.0 % to sulbactam-ampicillin, 37.9 % to cefaz-
olin, and 26.3 % to ciproﬂoxacin (CPFX) (Table 3). None
of the P. aeruginosa strains produced MBL. In P. aeru-
ginosa, the resistance rates were 7.4 % to tazobactam/
piperacillin (TAZ/PIPC), 10.2 % to imipenem (IPM),
2.8 % to meropenem (MEPM), cefepime (CFPM), and
CPFX, and 0 % to gentamicin (Table 3; Fig. 1). In
B. fragilis, the resistant rate was 28.6 % to clindamycin;
however, the incidence remained 5.7 % to cefmetazole. In
non-fragilis Bacteroides, including B. thetaiotaomicron,
high resistance rates to clindamycin and cefmetazole were
noted. Low rates of resistance to TAZ/PIPC, IPM, and
metronidazole were observed in both B. fragilis and non-
fragilis Bacteroides (Table 4).
Antibiotic susceptibility of P. aeruginosa according
to the duration of the postoperative hospital stay until
isolation was analyzed. When compared with MIC90 of
Table 2 Antibiotic susceptibility in methicillin-sensitive Staphylococcus aureus (MSSA), methicillin-resistant Staphylococcus aureus (MRSA),
and Enterococcus faecalis
Organism (number tested)
and antimicrobial agent
MIC (lg/ml) %
MIC50 MIC90 Range Susceptible Intermediate Resistant
MSSA (40)
Cefazolin 0.5 0.5 0.25–1 100 0 0
Cefmetazole 1 1 1–2 100 0 0
Cefepime 2 2 1–4 100 0 0
Ampicillin 0.5 8 0.125–16 47.5 – 52.5
Oxacillin 0.25 0.5 0.125–0.5 100 0 0
Ampicillin/sulbactam 0.5 2 0.125–4 100 0 0
Piperacillin/tazobactam 1 2 0.5–2 100 0 0
Imipenem 0.06 0.06 0.06–0.125 100 0 0
Meropenem 0.06 0.125 0.06–0.125 100 0 0
Doripenem 0.06 0.06 0.06–0.06 – – –
Biapenem 0.06 0.06 0.06–0.125 – – –
Panipenem 0.06 0.06 0.06–0.125 – – -
Levoﬂoxacin 0.25 0.5 0.125–8 95 0 5
Gentamycin 0.25 128 0.25–128 75 0 25
Minocycline 0.125 0.125 0.06–0.25 100 0 0
Clindamycin 0.25 0.25 0.25–0.5 100 0 0
Erythromycin 0.5 0.5 0.5–128 81.6 0 18.4
MRSA (103)
Vancomycin 1 1 0.5–2 100 0 0
Teicoplanin 1 2 0.25–8 100 0 0
Gentamycin 0.5 64 0.25–256 52.4 0 47.6
Arbekacin 0.5 1 0.25–8 – – –
Minocycline 8 16 0.06–32 43.7 10.7 45.6
Clindamycin 128 128 0.25–128 9.3 – 90.7
Erythromycin 128 128 0.25–128 7.8 0 92.2
Linezolid 2 2 1–4 100 0 0
Daptomycin 0.25 0.5 0.25–0.75 100 0 0
Sulfamethoxazole/trimethoprim 0.063 0.063 0.031–0.125 100 0 0
E. faecalis (137)
Ampicillin 1 2 0.5–8 100 0 0
Piperacillin 4 4 2–128 – – –
Imipenem 2 2 0.5–16 – – –
Levoﬂoxacin 2 64 1–128 83.9 2.2 13.9
Vancomycin 1 2 0.5–8 98.5 1.5 0
J Infect Chemother (2012) 18:816–826 819
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Table 3 Antibiotic susceptibility in Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Pseudomonas aeruginosa
Organism (number tested)
and antimicrobial agent
MIC (lg/ml) %
MIC50 MIC90 Range Susceptible Intermediate Resistant
Escherichia coli (95)
Cefazolin 1 C256 0.5 to C256 52.5 9.5 37.9
Cefmetazole 0.5 16 0.25 to 128 92.6 2.1 5.3
Ceftazidime 0.125 8 B0.06 to 128 89.5 2.1 8.4
Cefepime B0.06 4 B0.06 to 64 96.8 2.1 1.1
Ampicillin/sulbactam 4 32 1 to C256 56.8 23.2 20
Piperacillin/tazobactam 1 4 0.5 to C256 95.8 2.1 2.1
Imipenem 0.25 0.5 B0.06 to 1 100 0 0
Meropenem B0.06 B0.06 B0.06 to B0.06 100 0 0
Doripenem B0.06 B0.06 B0.06 to B0.06 – – –
Biapenem B0.06 B0.06 B0.06 to 0.125 – – –
Panipenem 0.125 0.25 B0.06 to 0.5 – – –
Aztreonam B0.06 8 B0.06 to 64 87.4 6.3 6.3
Ciproﬂoxacin B0.06 32 B0.06 to 128 73.7 0 26.3
Levoﬂoxacin 0.125 16 B0.06 to 32 73.7 1 25.3
Pazuﬂoxacin B0.06 8 B0.06 to 16 – – –
Gentamycin 0.5 2 0.25 to 128 90.5 0 9.5
K. pnemoniae (53)
Cefazolin 1 2 1 to C256 81.1 9.4 9.4
Cefmetazole 0.5 4 0.5 to C256 94.3 0 5.7
Ceftazidime 0.125 0.5 B0.06 to 32 98.1 0 1.9
Cefepime B0.06 0.125 B0.06 to 2 100 0 0
Ampicillin/sulbactam 4 16 2 to 64 88.7 5.7 5.7
Piperacillin/tazobactam 2 8 0.5 to 32 96.2 3.8 0
Imipenem 0.25 1 0.125 to 2 100 0 0
Meropenem B0.06 B0.06 B0.06 to 1 100 0 0
Doripenem B0.06 0.125 B0.06 to 1 – – –
Biapenem 0.125 0.5 B0.06 to 1 – – –
Panipenem 0.25 0.5 B0.06 to 2 – – –
Aztreonam B0.06 0.25 B0.06 to 2 100 0 0
Ciproﬂoxacin B0.06 0.25 B0.06 to 1 100 0 0
Levoﬂoxacin 0.125 1 B0.06 to 2 100 0 0
Pazuﬂoxacin B0.06 0.25 B0.06 to 1 – – –
Gentamycin 0.25 0.5 0.125 to 1 100 0 0
E. cloacae (58)
Cefmetazole C256 C256 64 to C256 0 0 100
Ceftazidime 0.5 64 B0.06 to 128 74.1 1.8 24.1
Cefepime B0.06 1 B0.06 to 8 100 0 0
Ampicillin/sulbactam 32 64 4 to 128 3.4 17.3 79.3
Piperacillin/tazobactam 2 64 0.5 to C256 81 13.8 5.2
Imipenem 1 2 0.25 to 2 100 0 0
Meropenem B0.06 0.125 B0.06 to 2 100 0 0
Doripenem B0.06 0.125 B0.06 to 1 – – –
Biapenem 0.125 0.25 B0.06 to 0.5 – – –
Panipenem 0.5 1 0.25 to 4 – – –
Aztreonam 0.25 32 B0.06 to 64 77.6 1.7 20.7
Ciproﬂoxacin B0.06 2 B0.06 to 32 89.7 1.7 8.6
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P. aeruginosa isolated within 7 days after surgery, that of
P. aeruginosa isolated 15 days or later after surgery rose
by eightfold in TAZ/PIPC and CAZ, by fourfold in IPM
and MEPM, and by twofold in CPFX, GM, and CFPM
(Fig. 2). In addition, the changes of antibiotic susceptibility
according to the duration of therapeutic antibiotic use were
evaluated. When compared with MIC90 of P. aeruginosa
isolated within 2 days of therapeutic antibiotic use, that of
P. aeruginosa with 8 days or more therapeutic antibiotic
use revealed a similar tendency of the alteration of anti-
biotic susceptibility, which was observed in the analysis
according to the duration of postoperative hospital stay
until isolation (Fig. 3). Antibiotic susceptibility was also
analyzed from the patient’s physical status classiﬁcation. In
patients with ASA score C3, the resistance rates of
P. aeruginosa to TAZ/PIPC and CAZ were higher than
those in patients with ASA B2 (Fig. 4).
Discussion
In a prevalence survey by the JHAIS, the main organisms
isolated from SSI were 2,182 strains (14.3 %) of Entero-
coccus faecalis, 2,167 strains (14.2 %) of Staphylococcus
aureus (MRSA, 1351 strains), 1,557 strains (10.2 %)
of Pseudomonas aeruginosa, 1,140 strains (7.5 %) of
Table 3 continued
Organism (number tested)
and antimicrobial agent
MIC (lg/ml) %
MIC50 MIC90 Range Susceptible Intermediate Resistant
Levoﬂoxacin 0.125 2 B0.06 to 16 93.1 5.2 1.7
Pazuﬂoxacin B0.06 1 B0.06 to 16 – – –
Gentamycin 0.25 0.5 0.25 to 4 100 0 0
P. aeruginosa (108)
Ceftazidime 2 16 0.5 to 64 89.8 3.7 6.5
Cefepime 2 8 0.25 to 32 91.7 5.5 2.8
Piperacillin/tazobactam 4 64 0.25 to C256 92.6 – 7.4
Imipenem 2 16 0.25 to 16 88 1.8 10.2
Meropenem 0.25 4 B0.06 to 16 93.5 3.7 2.8
Doripenem 0.25 4 B0.06 to 16 – – –
Biapenem 0.5 8 0.125 to 32 – – –
Panipenem 8 16 0.25 to 64 – – –
Aztreonam 4 16 0.5 to 64 66.7 19.4 13.9
Ciproﬂoxacin 0.25 0.5 B0.06 to 128 95.4 1.8 2.8
Levoﬂoxacin 1 2 0.125 to 128 91.7 5.5 2.8
Pazuﬂoxacin 0.5 1 B0.06 to 32 – – –
Gentamycin 2 2 0.5 to 4 100 0 0
Fig. 1 Antibiotic resistance
rate of Pseudomonas
aeruginosa for each antibiotic
J Infect Chemother (2012) 18:816–826 821
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Escherichia coli, 911 strains (6.0 %) of Enterobacter clo-
acae, 610 strains (4.0 %) of Staphylococcus epidermidis,
504 strains (3.3 %) of Bacteriodes fragilis group, and 446
strains (2.9 %) of Klebsiella pneumoniae [1]. We found
only a few reports concerning the antimicrobial suscepti-
bility of organisms isolated from SSI and, as far as we
know, this is the largest survey. Schnu¨riger et al. [11]
studied the microbiological proﬁle and antimicrobial
susceptibility in SSIs following hollow viscus injury.
Susceptibility rates of E. coli and E. cloacae, respectively,
were 38 and 8 % for ampicillin/sulbactam, 82 and 4 % for
cefazolin, 96 and 92 % for cefoxitin, with both 92 % for
PIPC/TAZ and 100 % for ertapenem.
The members of the B. fragilis group are the most
important anaerobic pathogens recovered from intraab-
dominal infections. Among the B. fragilis group isolates,
B. fragilis accounts for 40–54 % of the Bacteroides
isolates. Another important pathogen that belongs to the
B. fragilis group isolates is B. thetaiotaomicron, which
accounts for 13–23 % of the isolates. Other members of the
Table 4 Antibiotic susceptibility in Bacteroides fragilis group
Organism (number tested)
and antimicrobial agent
MIC (lg/ml) %
MIC50 MIC90 Range Susceptible Intermediate Resistant
B. fragilis (70)
Cefmetazole 8 32 4–128 82.9 11.4 5.7
Flomoxef 1 64 0.25–256 – – –
Ampicillin/sulbactam 1 8 0.5–256 90 5.7 4.3
Piperacillin/tazobactam 0.25 2 0.06–256 95.7 1.4 2.9
Imipenem 0.25 2 0.125–128 95.7 1.4 2.9
Meropenem 0.125 4 0.06–256 97.1 0 2.9
Doripenem 0.25 2 0.125–128 – – –
Biapenem 0.25 1 0.125–256 – – –
Panipenem 0.25 2 0.06–256 – – –
Clindamycin 0.5 256 0.06–256 70 1.4 28.6
Metronidazole 1 2 0.25–4 100 0 0
B. thetaiotaomicron (22)
Cefmetazole 32 64 16–64 4.5 59.1 36.4
Flomoxef 16 256 4–256 – – –
Ampicillin/sulbactam 1 4 1–4 100 0 0
Piperacillin/tazobactam 8 16 1–16 100 0 0
Imipenem 0.5 1 0.25–2 100 0 0
Meropenem 0.25 0.5 0.125–1 100 0 0
Doripenem 0.5 1 0.25–1 – – –
Biapenem 0.25 1 0.25–1 – – –
Panipenem 0.5 2 0.25–2 – – –
Clindamycin 256 256 0.5–256 31.8 9.1 59.1
Metronidazole 1 1 0.125–2 100 – –
Other Bacteroides sp. (10)
Cefmetazole 16 64 8–128 50 30 20
Flomoxef 8 256 0.5–256 – – –
Ampicillin/sulbactam 4 32 0.5–32 80 0 20
Piperacillin/tazobactam 2 4 0.5–4 100 0 0
Imipenem 1 2 0.25–8 90 10 0
Meropenem 0.25 2 0.125–4 100 0 0
Doripenem 0.5 2 0.125–8 – – –
Biapenem 0.5 1 0.25–1 – – –
Panipenem 1 4 0.5–4 – – –
Clindamycin 2 256 0.25–256 50 10 40
Metronidazole 1 2 0.06–1 100 0 0
822 J Infect Chemother (2012) 18:816–826
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Table 5 Distribution of
minimum inhibitory
concentrations (MIC) against
anti-MRSA drugs in MRSA
Antimicrobial agents % of organisms in each minimum inhibitory concentration
0.25 lg/ml 0.5 lg/ml 1 lg/ml 2 lg/ml 4 lg/ml 8 lg/ml
Vancomycin 1.9 88.3 9.8
Teicoplanin 2.9 42.7 37.9 14.6 2.0
Arbekacin 5.8 55.3 34.0 3.9 1.0
Linezolid 24.3 71.8 3.9
Daptomycin 54.3 41.7 3.9
Fig. 2 MIC90 against
Pseudomonas aeruginosa for
each antibiotic according to the
duration of postoperative
hospital stay until isolation.
MIC90 minimum inhibitory
concentration required to inhibit
the growth of 90 % of
organisms
Fig. 3 MIC90 against
Pseudomonas aeruginosa for
each antibiotic according to the
duration of therapeutic
antibiotic use until isolation.
MIC90 minimum inhibitory
concentration required to inhibit
the growth of 90 % of
organisms
J Infect Chemother (2012) 18:816–826 823
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B. fragilis group isolates account for 33–39 % [12, 13].
B. fragilis is generally the most susceptible, and B. theta-
iotaomicron is generally the most resistant [14].
Marked increases in the resistance of the B. fragilis
group relative to 20 years ago were observed for clinda-
mycin [12]. Among second-generation cephalosporins,
cefoxitin is the most effective against the B. fragilis group.
Cefotetan and cefmetazole were equally effective to
cefoxitin against B. fragilis but are inferior against other
members of the B. fragilis group isolates [12–14]. In our
study, a similar pattern was conﬁrmed in the SSI isolates.
Carbapenems, TAZ/PIPC, and metronidazole possess
excellent activity against B. fragilis group. Compared with
the organisms isolated from community-acquired intraab-
dominal infections, the antibiotic resistance rate of cefox-
itine and clindamycin tended to be higher in isolates from
nosocomial intraabdominal infections [15].
In the guideline for the diagnosis and management of
complicated intraabdominal infection by the Infectious
Diseases Society of America [16], ampicillin-sulbactam is
not recommended because of high rates of resistance to this
agent among E. coli, and quinolones should not be used
unless surveys indicate[90 % susceptibility of E. coli. In
our study, resistant E. coli strains were 20.0 % to sulbac-
tam-ampicillin and 26.3 % to CPFX, and these antibiotics
seem not to be recommended for the treatment of postop-
erative intraabdominal infections. Longer duration of
antimicrobial prophylaxis may cause a high resistance rate
of E. coli (37.9 %) isolated from SSI to cefazolin. At 48 h
after the end of surgery, 56.2 % of patients were still
receiving prophylaxis. Recently, ESBL-producing strains
have become prevalent in the community setting in Japan
[17]. In this survey, 11 of 95 E. coli strains (11.9 %) iso-
lated from SSI produced ESBL, but none of the strains
produced ESBL in K. pneumoniae. The low success rate of
vancomycin, and the poor prognosis of patients with
MRSA bacteremia, were demonstrated in vancomycin MIC
2 lg/ml strains [18]. In this study, 2 lg/ml strains
accounted for 9.7 %. Alternative therapy should be con-
sidered in the treatment of SSI if the vancomycin MIC is
2 lg/ml in MRSA.
In P. aeruginosa isolates from SSI, antibiotic suscepti-
bility tended to be superior to those from hospital-acquired
respiratory infections [19] and urinary tract infections [20].
Susceptibility of P. aeruginosa isolates from hospital-
acquired pneumonia and ventilator-associated pneumonia
by the SENTRY antimicrobial surveillance study were
72 %/66 % for gentamicin, 60 %/58 % for levoﬂoxacin,
70 %/65 % for cefepime, 72 %/66 % for meropenem, and
76 %/71 % for piperacillin/tazobactam, respectively[18].
Mathai et al. [19] reported that P. aeruginosa causing uri-
nary tract infections in hospitalized patients was most sus-
ceptible to amikacin (97.3 %)[ piperacillin ± tazobactam
(92.0–95.6 %)[ cefepime = imipenem (91.2 %)[ ceft-
azidime (85.8 %). Greatest resistance was observed to
ﬂuoroquinolone (24.8–39.8 %).
Acquisition of intrinsically resistant organisms and
selective pressure for resistance within a unit or hospital
are of increasing concern. Unnecessarily prolonged anti-
biotic use and needlessly broad coverage cause resistant
organisms. Mentzelopoulos et al. [21] reported that the sole
independent predictor of pandrug-resistant P. aeruginosa
ventilator-associated pneumonia (VAP) was the combined
use of carbapenem for more than 20 days and colistin use
for more than 13 days. Kusachi et al. [22] reported that the
incidence of strains resistant to cephems and carbapenems
increased as the number of different antimicrobial agents
used for the treatment of SSI increased. In general, anti-
microbial therapy of established intraabdominal infection
should be limited to 4–7 days, unless it is difﬁcult to
Fig. 4 Antibiotic resistance
rate in Pseudomonas aeruginosa
according to the American
Society of Anesthesiologists
(ASA) physical status
classiﬁcation score
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achieve adequate source control [15]. A common practice
in the treatment of incisional SSI is to open all infected
wounds. If there is minimal surrounding evidence of
invasive infection and systemic signs of infection, antibi-
otics are unnecessary. In cases indicated for antimicrobial
therapy, a duration of 24–48 h may be indicated [23].
In our study, isolation of MRSA (p\ 0.001) and
P. aeruginosa (p = 0.081) increased 8 days or later after
surgery. Antibiotic susceptibility of P. aeruginosa isolated
15 days or later after surgery decreased in TAZ/PIPC,
CAZ, IPM, and CPFX. MIC90 of P. aeruginosa with 8 days
or more therapeutic antibiotic use revealed a similar ten-
dency when compared with a shorter duration until isola-
tion. In addition, the patient’s preoperative status affected
the antibiotic susceptibility of organisms isolated from SSI.
In patients with ASA score C3, the resistance rates of
P. aeruginosa to TAZ/PIPC and CAZ were higher than
those in patients with ASA B2. A history of previous
hospitalization for reasons of comorbidity or the necessity
of prolonged antibiotic therapy in a compromised host with
comorbidity may cause lower antibiotic susceptibility of
isolates from SSI. In conclusion, the data obtained in this
study revealed the trend of the spread of resistance among
common species that cause SSI, and the need for contin-
uous monitoring was conﬁrmed.
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